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ABSTRACT 
NEURAL PRECURSORS OF APATHY AND DEPRESSIVE SYMPTOMS IN 
AMNESTIC MILD COGNITIVE IMPAIRMENT 
SEPTEMBER 2021 
MOLLY A. MATHER, B.A., POMONA COLLEGE 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Rebecca E. Ready 
Depressive symptoms and apathy are common in amnestic mild cognitive 
impairment (aMCI) and are associated with increased risk of conversion to Alzheimer’s 
disease (AD). The shared neuropathological model of neuropsychiatric symptoms (NPS) 
in AD suggests that symptoms of depression and anxiety represent noncognitive 
manifestations of neuropathological changes. Neurodegeneration in aMCI occurs in areas 
of the brain that support emotion regulation, including the limbic system and prefrontal 
control regions. Depression and apathy in aMCI have been linked to atrophy in the limbic 
system and prefrontal cortex and reduced connectivity in resting-state networks. 
However, it is not yet established whether neural changes in emotion centers in the brain 
predict symptoms of depression and apathy in persons with aMCI, or whether neural 
precursors in the limbic system and prefrontal cortex are associated with higher risk of 
conversion from aMCI to AD. The current study utilized longitudinal clinical and 
neuroimaging data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to 
determine whether change in neural structure and function in emotion centers predicted 
symptoms of depression and apathy in aMCI and conversion to AD. Depressive 
v 
symptoms and apathy increased over time, and cortical volume in emotion centers in the 
brain decreased over time, especially in the MCI group. The slope of change in neural 
markers was not correlated with the slope of change in depressive symptoms or with the 
presence versus absence of apathy. Presence of apathy, slope of change in depressive 
symptoms, and speed of atrophy in the amygdala and cingulate cortex predicted 
progression of disease. Overall, results provided limited support for the shared 
neuropathological model of NPS in aMCI, primarily related to amygdala atrophy. Future 
research is needed to further define the role of neurodegeneration in emotion centers in 
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Amnestic mild cognitive impairment (aMCI) is a condition that often precedes 
Alzheimer’s disease (AD; Xie et al., 2017; Ye et al., 2012). Estimates for the prevalence 
of aMCI in the older adult population range from 4 to 12% (Ganguli et al., 2004; Katz et 
al., 2012; Lopez et al., 2003; Peterson et al., 2010; Plassman et al., 2008) and between 11 
and 17% of persons with aMCI convert to AD annually (Ganguli et al., 2004; Plassman et 
al., 2008). aMCI is associated with increased healthcare expenditures (Albert et al., 2002) 
and higher utilization of informal caregiving compared to cognitively healthy older adults 
(Zhu et al., 2013). 
aMCI is characterized by memory impairment in the absence of significant 
functional impairment in activities of daily living (Peterson et al., 2009). Several markers 
for conversion from aMCI to AD are well established, including deficits in episodic 
memory (e.g., Ye et al., 2012), neuropathology of the medial temporal lobe (e.g., Dubois 
et al., 2016), and genetic factors (Jack et al., 2018). Emotion dysregulation—often 
indicated by depressive symptoms and apathy—is a less well understood marker for 
conversion from aMCI to AD. Knowledge about the neural precursors of depressive 
symptoms and apathy in persons with aMCI may augment our ability to predict who is at 
highest risk for progression to AD. 
Emotion dysregulation is indicated by difficulty modulating the experience and 
expression of emotion (e.g., Gross, 2002). Emotion dysregulation manifests in depressive 
symptoms and apathy in the form of reduced ability to mount emotional responses and 
difficulty modulating negative affective states. Depressive symptoms and apathy in 
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persons with aMCI may result from neuropathological changes in regions of the brain 
that support emotion responding and regulation. Indeed, neurodegeneration in aMCI and 
AD occurs in regions of the brain that are known to support emotion regulation, including 
the amygdala, insula, anterior cingulate cortex (ACC), and prefrontal cortex (PFC; Karas 
et al., 2004; Killiany et al., 2000; Prieto del Val et al., 2016). Neural changes in aMCI 
involve both structural decline (e.g., grey matter atrophy) and functional disruptions (e.g., 
decreased or increased activity within and between networks).  
It is well-established that the neuropathology of AD (e.g., atrophy in the medial 
temporal lobes, especially the hippocampus) precedes clinically-apparent memory 
decline. It is not yet clear if neural changes predict clinically-apparent symptoms of 
apathy and depression in aMCI. Additionally, it is not clear whether change in such 
neural markers is associated with progression from aMCI to AD. The present study 
addresses these gaps in the literature by investigating the longitudinal associations 
between neural changes in emotion centers of the brain and change in symptoms of 
depression and apathy. If we are able to identify early neural markers of increase in 
symptoms of depression and apathy in aMCI, this may improve our ability to predict who 
is at risk for clinically-apparent symptoms of depression and apathy. The present study 
will also address whether early neural markers of depression and apathy are predictive of 
conversion from aMCI to AD. Findings may identify subgroups of persons with aMCI 
that would benefit most from preventative interventions for neuropsychiatric symptoms 





1.1 Apathy and Depressive Symptoms in Persons with aMCI  
Apathy is defined by a lack of motivation and/or interest in daily activities 
(Marin, 1990). Depressive symptoms include sadness, irritability, hopelessness, 
decreased positive affect, social withdrawal, and loss of energy (American Psychiatric 
Association, 2013). Apathy and depressive symptoms are common in neurological 
populations and are often co-morbid, but are conceptualized as distinct 
neuropsychological constructs (e.g., Levy et al., 1998). Surprisingly, though, there is 
substantial overlap in the neural correlates of depressive symptoms and apathy in older 
adult samples. Specifically, both depressive symptoms and apathy have been linked to 
reduced grey matter volume in the ACC (e.g., Bruen et al., 2008; Disabato & Sheline, 
2012) and to reduced DMN connectivity (e.g., Joo et al., 2017; Wu et al., 2011). This 
overlap in the correlates of apathy and depression may be at least in part due to 
commonalities in the way the constructs are operationalized and measured (Mortby et al., 
2012). Confounding of symptoms of apathy and depression in prior research has likely 
contributed to a lack of clarity with regard to distinct neural correlates. Depressive 
symptoms and apathy are conceptualized as transdiagnostic markers of emotion 
dysregulation in aMCI in the current study because the extant literature limits our ability 
to delineate the distinct neural correlates of these symptoms. 
Apathy and depressive symptoms are the most commonly reported NPS in aMCI 
(e.g., Apostolova & Cummings, 2008). Approximately 26-50% of persons with aMCI 
exhibit depressive symptoms and 20-35% exhibit apathy (Di Iulio et al., 2010; Geda et 
al., 2008). Further, these symptoms are highly comorbid; between 37% and 58% of 
persons with MCI that report apathy also report depressive symptoms (Chilovi et al., 
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2009; Zahodne & Tremont, 2013). Depressive symptoms and apathy are distressing for 
persons with aMCI and for their caregivers (Ryan et al., 2012; Teng et al., 2012) and are 
more predictive of quality of life than cognitive impairment (Ready et al., 2004; Teng et 
al., 2012). Further, NPS in AD are associated with higher informal care costs (Rattinger 
et al., 2019) and risk for institutionalization (Okura et al., 2012). 
 Apathy and depressive symptoms in aMCI are associated with a higher likelihood 
of conversion to AD (Lu et al., 2009; Mallo et al., 2020; Modrego & Ferrandez, 2004; 
Palmer et al., 2010; Richard et al., 2012; Ruthirakuhan et al., 2019; Van der Mussele et 
al., 2014). More generally, persons with aMCI that were classified as having affective 
symptoms were twice as likely as persons without affective symptoms to convert to AD 
(Forrester et al., 2016). Further, affective dysregulation added prognostic accuracy for 
development of MCI and AD above hippocampal atrophy (Gill et al., 2020). 
1.2 Etiology of Neuropsychiatric Symptoms in aMCI and AD 
There are several theories about the neurobiology of NPS in AD. The etiological 
model posits that NPS lead to the development of AD; the reactive model suggests that 
NPS develop as a psychological reaction to AD; the interactive model predicts that NPS 
and other risk factors interact to cause AD; and the shared neuropathology model 
hypothesizes that NPS reflect noncognitive manifestations of AD neuropathology (Geda 
et al., 2013; Porsteinsson & Antonsdottir, 2015). The shared neuropathology model 
provides a useful framework for investigating the etiology of NPS in aMCI, as it mirrors 
well-supported models of the neurobiology of cognitive decline in persons with aMCI 
and AD (e.g., Blasko et al., 2008; Ferreira et al., 2011; Li et al., 2016; Whitwell et al., 
2008). That is, neuropathological changes in the medial temporal lobe lead to initial 
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decline in memory, followed by more general decline in cognitive and functional abilities 
as neurodegeneration progresses and affects additional structures and circuits. Based on 
the shared neuropathological model, neuropathological changes in structures and circuits 
of the brain that support emotional function (e.g., the limbic system and frontal lobes) 
occur in aMCI; NPS arise—at least partially—as a result of the same neuropathological 
changes that cause cognitive decline and functional impairment. According to this model, 
NPS in AD reflect non-cognitive manifestations of the underlying neuropathology of the 
disease. The shared neuropathology model offers the potential to develop an integrative 
theory of the neurobiology of diverse symptoms (e.g., cognitive decline, NPS) in aMCI.  
Empirical evidence for the shared neuropathology model of NPS in AD remains 
limited (Van Dam et al., 2016). This model has only been applied in AD and has not been 
tested in persons with aMCI. AD neuropathology begins well before the onset of 
clinically-apparent symptoms, and neuropathological changes in emotion centers in the 
brain are apparent even in aMCI (e.g., Csukly et al., 2016; Killiany et al., 2000; Yi et al., 
2016). The shared neuropathological model of NPS in AD implies that NPS are a 
consequence of neurodegeneration, which may help explain the association between NPS 
and risk for conversion to AD. That is, the presence of NPS may signal more advanced 
neuropathology, or neuropathology in key regions, in aMCI.  
 
1.3 Neurobiology of Emotion Dysregulation in aMCI 
During emotion regulation in healthy older adults, the amygdala and insula are 
activated in response to emotional stimuli, and emotional arousal is hypothesized to be 
modulated and down-regulated by cognitive control regions, such as the ventromedial 
prefrontal cortex (vmPFC), ventrolateral medial prefrontal cortex (vlPFC), and anterior 
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cingulate cortex (ACC; Dolcos et al., 2014; Mather, 2016; Winecoff et al., 2011). 
Effective emotion regulation thus involves the mounting of an emotional response by 
subcortical limbic structures and appropriate modulation of negative emotional states by 
cognitive control regions (e.g., Green & Mahli, 2006; Ochsner et al., 2012). Emotion 
regulation is also supported by the default mode network (DMN), which encompasses the 
posterior cingulate cortex (PCC), medial PFC, and medial temporal lobes (e.g., Gusnard 
& Raichle, 2001; Raichle et al., 2001). The DMN is implicated in self-reflective 
processing and emotion awareness (e.g., Martins & Mather, 2016; Prakash et al., 2013) 
and supports aspects of emotion regulation that involve assigning personal meaning to 
stimuli and situations. Inversely, emotion dysregulation occurs as the result of 
disturbance in one or more of the component parts of the emotion regulation system. 
Difficulties with emotion dysregulation may occur as the result of damage to the 
hardware (e.g., structural atrophy) or software (e.g., reduced functional connectivity) of 
the emotion regulation system. 
Neurodegeneration in aMCI occurs in a number of areas of the brain implicated in 
emotion dysregulation. Significant gray matter atrophy is found in the amygdala (Csukly 
et al., 2016; Poulin et al., 2011; Yi et al., 2016), insula (Karas et al., 2004), ACC 
(Killiany et al., 2000), and PCC (Bailly et al., 2015; Trivedi et al., 2006) in persons with 
aMCI. Atrophy in these areas of the brain likely undermines the ability to effectively 
regulate emotions.  
In addition to structural changes, persons with aMCI demonstrate functional 
changes in neural regions associated with emotion dysregulation. Persons with aMCI 
exhibit lesser spontaneous activity in the medial PFC compared to healthy controls (Cai 
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et al., 2017; Ren et al., 2017). In persons with aMCI relative to controls, increases and 
decreases in spontaneous activity in the amygdala (Cai et al., 2017; Han et al., 2012) and 
ACC are observed (Gold et al., 2010; Ren et al., 2017), which may indicate less stability 
in emotion function in persons with aMCI. Compared to healthy older adults, persons 
with aMCI demonstrate decreased functional connectivity within the DMN (Cai et al., 
2017; Joo et al., 2017; Palmqvist et al., 2017; Wang et al., 2012; Yi et al., 2015). Persons 
with aMCI also exhibit reduced functional connectivity between the amygdala and 
prefrontal/fronto-parietal areas (Ortner et al., 2016).  
 
1.4 Neurobiology of Depressive Symptoms and Apathy in aMCI 
Emotion dysregulation is a multifaceted construct that encompasses difficulties 
with the generation, expression, and modulation of emotion (e.g., Mennin et al., 2007). 
Emotion dysregulation, in its many forms, makes up a core component of many 
psychiatric disorders (e.g., Bradley et al., 2011). When examined from a lifespan 
developmental perspective, emotion dysregulation appears to serve as a mechanism for 
the development of psychopathology (Cole et al., 2008). Observed NPS (e.g., apathy, 
depressive symptoms) are thus—at least in part—a reflection of dysregulated affective 
processes. In order to definitively determine the neural mechanisms of NPS in aMCI and 
AD, it will be necessary to study the direct links between specific neural structures and 
circuits, aspects of emotion dysregulation, and the symptoms that arise as a result of these 
pathways. The extant knowledge base is far from this eventual goal. However, NPS have 
proven to be useful proxy variables to begin to delineate links between neural changes in 
aMCI and development of NPS.  
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Apathy and depressive symptoms both reflect aspects of emotion dysregulation. 
Both conditions reflect emotion dysregulation via blunting of affective responses and 
reduced goal-directed behaviors, and depressive symptoms additionally involve difficulty 
modulating negative affect states. Both apathy and depressive symptoms can be 
conceptualized to reflect “negative” symptoms in that they typically involve the absence 
of wanted behaviors, resulting in negative outcomes (e.g., flat affect, withdrawal, 
isolation).  
The neural structures and circuits that are implicated in the development of 
symptoms of depression mimic those that are involved in emotion dysregulation more 
generally. The cognitive-biological model of depression posits that depressive symptoms 
involve decreased mounting of emotional responses (e.g., hypoactivity in the amygdala) 
and lesser down-regulation of negative emotions (e.g., atrophy or hypoactivity in the 
PFC; Disner et al., 2011). Persons with aMCI and depressive symptoms demonstrate 
greater atrophy in frontal white matter volume relative to persons with aMCI without 
depressive symptoms (Lee et al., 2012). Depressive symptoms are associated with frontal 
lobe dysfunction (i.e., lower glucose metabolism in the frontal superior gyrus) in persons 
with AD (Lee et al., 2006). 
Late-life depression is associated with atrophy in the amygdala and ACC 
(Disabato & Sheline, 2012) and in the PCC (Ries et al., 2009). Additionally, depressive 
symptoms in older adults are associated with reduced activity in the frontal lobes 
(Viitanen et al. , 2007) and reduced activity in the vmPFC during emotional tasks 
(Brassen et al., 2008). Late-life depression is also associated with reduced DMN 
connectivity (Wu et al., 2011).  
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The neural structures and circuits implicated in symptoms of apathy also 
demonstrate overlap with regions involved in emotion dysregulation more generally. 
Apathy is linked to atrophy in the bilateral ACC in persons with aMCI and AD 
(Apostolova et al., 2007; Bruen et al., 2008; Stanton et al., 2013), and to atrophy in 
frontal-subcortical circuits in MCI (Johansson et al., 2020) and AD (Starkstein et al., 
2014). Apathy is associated with lower functional connectivity in the DMN (Joo et al., 
2017), reduced blood flow in the frontal lobes as measured by PET imaging (Kazui et al., 
2017), and hypometabolism in the PCC (Ng et al., 2019) in persons with aMCI. Affective 
dysfunction, particularly apathy, is associated with decreased functional connectivity in 
the frontal-parietal control network in persons with aMCI (Munro et al., 2015).  
Studies of the neural correlates of apathy in older adult and late-life depression 
samples provide additional evidence for the role of the ACC and PCC in apathy. In older 
adults without cognitive impairment, symptoms of apathy are associated with reduced 
grey matter volume in the ACC (Lavretsky et al., 2007). Associations between apathy 
and gray matter atrophy in the ACC and dorsolateral PFC are found in a variety of 
neurological and psychiatric populations, including AD (Kos et al., 2016). Among 
persons with late-life depression, those with symptoms of apathy evidence greater tau and 
amyloid burden in the ACC, indicating higher risk for development of AD (Eyre et al., 
2017). Improvements in apathy in geriatric depression are associated with greater volume 
in the PCC (Yuen et al., 2014).  
To date, most studies that have examined neural correlates of apathy and 
depressive symptoms in aMCI have focused on cross-sectional comparisons between 
healthy controls and persons with aMCI. One longitudinal study examined the link 
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between neural changes and depressive symptoms in persons with aMCI. Gonzales et al. 
(2017) found that persons with stable subsyndromal depression in aMCI displayed more 
accelerated cognitive decline than those without depressive symptoms, which was 
accounted for by gray matter atrophy in the ACC and frontal lobes. Thus, there is 
preliminary support for the utility of examining change in neural structures in relation to 
depressive symptoms and progression of disease in aMCI. Whereas Gonzales et al. 
(2017) focused on depressive symptoms as a risk factor for disease progression, they did 
not address the timing of change in neural structures versus change in symptoms of 
depression. The current study will build on the findings of Gonzales et al. (2017) by 
focusing on the temporal associations between change in neural markers and change in 
symptoms of both apathy and depression. 
 
1.5 The Present Study 
Despite the prevalence and adverse consequences of depressive symptoms and 
apathy in persons with aMCI, the neurobiology of these symptoms is not yet established. 
The shared neuropathological pathway model suggests that depressive symptoms and 
apathy may arise as a result of early neuropathological changes. However, it is not yet 
clear whether neural changes precede symptoms of depression and apathy in aMCI, or 
whether identification of neural changes may increase our ability to predict development 
of affective symptoms and conversion from aMCI to AD. Using longitudinal behavioral 
and neuroimaging data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), 
the first aim of this study was to determine longitudinal associations between changes in 
neural structure and function of key emotion regions and circuits, and depressive 
symptoms and apathy in persons with aMCI and AD. Depressive symptoms and apathy in 
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persons with aMCI and AD are hypothesized to be associated with atrophy and reduced 
resting-state connectivity in core emotion centers in the brain (i.e., amygdala, ACC, and 
PCC, and reduced resting-state connectivity within the DMN), and it is expected that 
these changes will be associated with worsening of depressive symptoms and apathy.  
The neural regions and circuits of interest are derived from well-established neural 
correlates of affective dysregulation in old age (e.g., Dolcos et al., 2014; Mather, 2016; 
Winecoff et al., 2011) and from structural and functional changes associated with 
depression and apathy in aMCI and AD (e.g., Bruen et al., 2008; Joo et al., 2017; Lee et 
al., 2012; Starkstein et al., 2014). The second aim of the current study was to determine 
whether change in neural structures and circuits of interest (i.e., amygdala, ACC, PCC, 
and DMN) predicts higher likelihood of progression of disease (i.e., CN to MCI or MCI 
to AD). Results from the current study will help delineate the temporal association 
between neural changes and symptoms of apathy and depression. If hypotheses are 









2.1 Data Source 
Data for the current study were obtained from the ADNI database 
(adni.loni.usc.edu). ADNI was launched in 2003 as a public-private partnership, led by 
Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI is to test 
whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), 
other biological markers, and clinical and neuropsychological assessment can be 
combined to measure the progression of aMCI and early Alzheimer’s disease (AD). For 
up-to-date information, see www.adni-info.org.  
2.2 Participants 
All ADNI participants are between the ages of 55 and 90 at enrollment. 
Participants are assigned to study groups based on performance on the Mini-Mental 
Status Exam (MMSE), Wechsler Memory Scale Logical Memory II (WMS LMII), and 
Clinical Dementia Rating (CDR). Cognitively normal (CN) participants score in the 
normal range on the MMSE, WMS LMII, and CDR and report no memory complaints or 
functional deficits. aMCI participants score in the normal range for the MMSE, score 0.5 
on the CDR, demonstrate abnormal performance on WMS LMII, and report a memory 
complaint. At each study visit, diagnosis is coded categorically (i.e., CN vs. MCI vs. 
AD), and any diagnostic change is noted. Inclusion criteria for all participants are fluency 
in English or Spanish, at least a 6
th
 grade education, and a score less than 6 on the GDS at 
entry into the study. Exclusion criteria for all participants include diagnosis of any 
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neurologic disease (other than suspected AD for the MCI group); evidence of infection, 
infarction, or focal lesions on the screening MRI; diagnosis of Major Depressive Disorder 
within the prior two years; history of schizophrenia; and diagnosis of substance or 
alcohol abuse within the prior two years. Additional inclusion criteria for the current 
study are data were at least two 3T MRI scans that passed quality control evaluation and 
at least two timepoints with NPS ratings to allow for longitudinal analyses, resulting in 
563 eligible subjects (n = 224 CN; n = 339 MCI; Figure 1). CN and MCI subjects did not 
differ in age at baseline and had similar education attainment. Compared to the CN 
sample, MCI subjects were more likely to identify as male, White, and Non-
Hispanic/Latino (see Table 1). The majority of subjects (66%) had at least two years of 
follow-up (range: 0.5-8 years); mean years of follow-up was significantly longer in the 
CN than the MCI group (Table 1 ).  
2.3 Measures 
2.3.1 Cognitive Screening 
The MMSE is a brief measure of global cognitive function (Folstein et al., 1975). 
The MMSE assesses orientation, attention, recall, language, and the ability to follow 
simple verbal commands. The MMSE demonstrates excellent test-retest reliability when 
administered from 24 hours to 28 days apart (rs = .83 to .98; Folstein et al., 1975). 
Concurrent validity of the MMSE is demonstrated via large correlations with verbal and 
performance IQ scores on the WAIS (rs = .66 to .78). The MMSE effectively identifies 
persons with cognitive impairment with high sensitivity (80%) and specificity (100%; 
Schramm et al., 2002). All CN and MCI participants scored in the normal range on the 
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MMSE at enrollment (i.e., 24-30). In the current sample, the CN group scored 
significantly higher on the MMSE than the MCI group at baseline (Table 1). 
2.3.2. Dementia Rating 
The Clinical Dementia Rating (CDR) scale (Morris, 1997) was developed to 
evaluate the severity of dementia. The CDR assesses the extent of deficits in memory, 
orientation, judgment, problem-solving, community and domestic activities, and personal 
care. The CDR demonstrates good interrater reliability (ICC > 80%), concurrent validity 
(rs range from .30-.70 across studies), and strong diagnostic validity (Olde Rikkert et al., 
2011). In the current sample, the CN group scored significantly lower on the CDR at 
baseline than the MCI group (Table 1).  
2.3.3 Apathy 
Apathy was assessed at baseline and each mid-year study visit with the 
apathy/indifference item on the Neuropsychiatric Inventory Questionnaire (NPI-Q; i.e., 
“Does the patient seem less interested in his/her usual activities or in the activities and 
plans of others?”; Kaufer et al., 2000). The NPI-Q is a brief self-administered 
questionnaire. Informants indicate the presence versus absence of 12 neuropsychiatric 
symptoms in the prior 4 weeks; for endorsed items, informants subsequently rate the 
severity of the symptom on a three-point scale (i.e., 1 = mild, 2 = moderate, 2 = severe). 
The NPI-Q demonstrates excellent test-retest reliability (r = .80 for total symptom count; 
r = .94 for symptom severity score) and convergent validity via strong correlations with 
the original interview form of the NPI (rs = .71-93 for individual symptoms; Kaufer et 
al., 2000).  
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2.3.4 Depressive Symptoms 
Depressive symptoms were assessed at baseline and at each yearly study visit 
using the Geriatric Depression Scale Short Form (GDS-SF; Sheikh & Yesavage, 1986). 
The GDS-SF is a 15-item self-report measure specifically developed to measure 
depression in older adults; items are rated on a “yes/no” basis. The GDS-SF was adapted 
from the original 30-item GDS (Brink et al., 1982), which exhibits excellent internal 
consistency (alpha = .94), split-half reliability (r = .94), and test-retest reliability (r = .85; 
Yesavage et al., 1983). The GDS-SF is highly correlated with the original GDS (I = .84, I 
< .001) and is able to differentiate depressed from non-depressed older adults, including 
those with mild to moderate dementia (Sheikh & Yesavage, 1986). The GDS-SF 
demonstrates good concurrent validity via strong correlations with other measures of 
depression (Herrmann et al., 1996). In the current sample, baseline GDS-SF scores were 
higher in the MCI group than the CN group, although both groups were well below the 
clinical cutoff for depression (Table 1). 
2.4 Procedures 
Participants enrolled in ADNI undergo an initial screening assessment, during 
which demographic, clinical, medical, and neuropsychological information is collected. 
Participants also undergo a baseline 3T fMRI within two weeks of the initial screening 
visit. Subsequent study visits are conducted at every six months from baseline. The 
MMSE, CDR, and GDS were administered at the annual visits, along with structural and 
functional MRI scans. The NPI-Q was administered at mid-year visits.  
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2.5 Imaging Procedures 
All scans were conducted on a 3T scanner. Participants were screened for 
standard MRI precautions. The scan procedures consisted of the following sequence: 
localizer, sagittal MP-RAGE, accelerated MP-RAGE, resting state fMRI (with eyes 
open), axial T2-FLAIR, axial T2-Star, axial ASL perfusion, axial DTI scan. All scans 
were reviewed for quality control at Mayo Clinic. 
2.5.1 Imaging Pre-processing 
Standardized imaging datasets were used for structural and functional imaging 
analyses. Within these standardized datasets, all MPRAGE images were pre-processed 
using gradient warping, scaling, B1 correction, and N3 inhomogeneity correction by 
Mayo Clinic. Pre-processed structural images were then run through FreeSurfer version 
5.1 using longitudinal processing. This approach allows for registration of images to a 
within-subject template space. Longitudinal processing steps included motion correction 
and registration, non-uniform intensity normalization, Talairach transform computation, 
intensity normalization, and segmentation. For the current study, cortical volume 
measures for the amygdala, caudal ACC (cACC), rostral ACC (rACC), and PCC were 
derived from standardized structural MRI datasets.  
Additional preprocessing of functional MRI data included the following steps: 
discarding the first 3 volumes, slice time correction, realignment, normalization to SPM5 
EPI template, smoothing with 4 mm full-width half maximum Gaussian kernel, linear 
detrending to correct for signal drift, and 0.01-0.08 Hz bandpass filtering. Linear 
regression correction included rigid body transformation motion effects. DMN 
connectivity was derived by extracting the average time course for each ROI (i.e., 
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anterior DMN [aDMN] and posterior DMN [pDMN]) and comparing to the time course 
of each voxel within the respective ROI using Pearson’s product-moment correlation 
coefficient. The median ROI-to-voxel (RV) correlation within each ROI was extracted; 









DATA ANALYTIC PLAN 
Due to the nested structure of the data (i.e., repeated measures at Level 1 nested 
within individuals at Level 2), I utilized multilevel longitudinal structural equation 
models to address study aims. Typical GLM-based analyses used for imaging studies 
cannot account for the repeated measures of longitudinal data, so Level 1 parameter 
estimates for imaging variables were obtained from standardized ADNI imaging datasets 
and used in parallel process latent growth models and lagged analyses in Mplus version 8 
(Muthen & Muthen, 1998-2012). Parallel process latent growth models and lagged 
analyses address the study aims from two vantage points. Parallel process models 
establish whether change in neural markers is associated with change in symptoms of 
depression or apathy, whereas lagged analyses allow for determination of temporal 
precedence of neural markers vs. behavioral symptoms. Results from these analyses 
provide complimentary data about the nature and timing of associations between neural 
precursors and symptoms of depression and apathy in aMCI. 
To investigate Aim 1 (i.e., whether longitudinal change in neural markers is 
associated with longitudinal change in depressive symptoms and apathy), I first 
conducted parallel process latent growth models, in which latent growth factors are 
estimated for the predictor (e.g., grey matter volume in the amygdala) and outcome (e.g, 
depressive symptoms). For the current study, parallel process models are useful because 
they estimate associations between change in variables over time (Madhyastha et al., 
2018; Telzer et al., 2018); these models addressed whether neural changes over the 
course of the study are associated with change in symptoms of depression and/or apathy. 
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In parallel process models, the primary outcome of interest was the association between 
latent growth factors for the predictor and outcome. That is, models determined whether 
there were associations between change in neural structure/function and change in 
symptoms of depression or apathy. 
In order to determine whether change in neural variables and symptoms of 
depression/apathy are specific to neuropathological changes in aMCI/AD, I included 
group as a between-group covariate in parallel process models. Participants were divided 
into (1) those that entered the study as CN and remained CN for all study visits, and (2) 
those that started as MCI or progressed from CN to MCI or AD during the study (i.e. 
cognitively impaired [CI] group). If slopes of change in neural markers and NPS are 
steeper in the CI group than in the CN group, this would provide conceptual support for a 
specific role for disease-related neurodegeneration in the disruption of emotion circuits 
and development of NPS in aMCI and AD, versus typical brain and behavior changes 
over time in older adults. 
Parallel process models are not able to directly address the temporal course of 
change in neural structures/function and change in symptoms of depression or apathy; I 
thus conducted lagged analyses to determine the specific temporal course of the 
association between neural changes and change in symptoms of depression and/or apathy. 
Lagged models determine whether variables predict themselves at later timepoints, and/or 
whether they predict other study variables at later timepoints. Though these models 
cannot determine causality, they can provide conceptual support for temporal precedence 
between variables. If hypotheses are supported for lagged analyses, these models will 
suggest that earlier neural volume and connectivity predict later symptoms of apathy and 
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depression. This result would be consistent with models of the neurobiology of NPS in 
aMCI and AD that posit that NPS may arise as a result of neural changes in emotion 
centers in the brain. I also concurrently tested alternate theories of the etiology of NPS in 
aMCI and AD in addition to the shared neuropathology model. I included predictive 
pathways from behavioral variables to neural variables; significant pathways in these 
models would provide evidence consistent with the etiological model of NPS (i.e., that 
NPS contribute to the development of aMCI/AD neuropathology). If both neural and 
behavioral variables predict each other at later time point, this would suggest a more 
complex picture of the neurobiology of apathy and depressive symptoms in aMCI in 
which neural changes and NPS form a feedback loop that compounds risk for worsening 
symptoms and progression of disease. 
I addressed Aim 2 (i.e., whether neural precursors are associated with disease 
progression) using parallel process models. I added an additional binary outcome variable 
(i.e., conversion to MCI or AD) to parallel process models to determine if growth in 
depressive symptoms and/or neural variables was associated with higher likelihood of 








4.1 Preliminary Analyses 
Descriptive statistics were examined to evaluate the data for normality and 
outliers. There was a significant, but small, positive correlation between depressive 
symptoms and apathy at baseline (ρ = .26 p < .001), supporting the inclusion of 
depressive symptoms and apathy as distinct outcomes in analyses. Age was included as a 
covariate due to significant correlations with the outcome variables, which included 
depressive symptoms, apathy, and conversion of disease (p < .05; Table 2). Patient 
education was included as an additional covariate due to a significant group difference in 
education attainment between baseline CN and baseline MCI groups (Table 1). 
 Data were transformed where appropriate to approach normality. Scores on the 
GDS were log-transformed due to significant positive skew. Endorsement of apathy was 
rare, with limited variability in severity ratings, creating a significantly positively-skewed 
distribution; apathy scores were dichotomized to reflect the presence versus absence of 
apathy at each timepoint. Bilateral cortical volume measurements were averaged to create 
a single measure of cortical volume for each neural structure of interest. Variables were 
scaled when appropriate to enable Mplus analyses. 
4.2 Longitudinal Associations Between and Neural Markers and NPS 
To address Aim 1—whether change in neural markers is associated with change 
in depressive symptoms and/or apathy—parallel process models were conducted that 
estimated concurrent growth curves for depressive symptoms and each neural marker 
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(Table 3; Figure 2). Ten separate models were planned for each combination of predictor 
(i.e., amygdala, cACC, rACC, and PCC volume; DMN connectivity) and outcome 
variable (i.e., depressive symptoms, apathy). However, the majority of subjects (84.9%) 
did not display variance in apathy scores over time, resulting in inadequate variance to 
warrant estimation of a growth curve process for apathy scores. Thus, parallel process 
models were not conducted with apathy; instead, apathy was entered as a dichotomous 
variable at Level 2 (i.e., whether a person ever displayed apathy vs. not) in latent growth 
models to assess for differences in mean slope of change in neural markers based on the 
presence of apathy.  
4.2.1 Baseline Group Differences 
At baseline, the CI group (i.e., subjects who entered the study as MCI or who 
started as CN but progressed to MCI or AD) had a higher level of depressive symptoms 
than the CN group. Amygdala volume was significantly smaller in the CI than the CN 
group. There were no significant group differences in cACC, rACC, or PCC volume or 
DMN connectivity at baseline. 
4.2.2 Growth in Variables Over Time 
Symptoms of depression increased over time for the entire sample; the slope of 
change in depressive symptoms was not significantly different between CN and CI 
groups. There was a significant negative slope for amygdala, cACC, rACC, and PCC 
volume in the overall sample, and each of these associations were moderated by group 
such that the CI group demonstrated a significantly more negative slope than the CN 
group. That is, there was faster atrophy in neural structures involved in emotion 
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regulation in CI subjects compared to CN subjects. There was not a significant slope of 
change for DMN connectivity in the overall sample, nor significant change for either 
group. 
4.2.3 Associations Between Growth Curves 
Contrary to predictions, the slope of change in depressive symptoms was not 
significantly correlated with the slope of change in the amygdala, cACC, rACC, and PCC 
volumes or in DMN connectivity. 
4.2.4 Moderation of Neural Slopes by Apathy 
Due to a small number of subjects with apathy – and thus low variability of 
apathy both within and between subjects – parallel process models were not conducted 
with apathy. Instead, apathy was entered as a between-subject dichotomous variable (i.e. 
persons with apathy endorsed at one or more timepoints versus those without apathy at 
any timepoint) in latent growth models to assess for moderation of slope in neural 
markers. There was not a significant difference in slope for subjects with and without 
apathy for any of the neural targets (Table 4).  That is, persons with apathy did not 
exhibit significantly greater change in neural structure or circuits over time than 
participants without apathy.  Persons with apathy had smaller rACC volumes at baseline 
than persons without apathy.  
4.2.5 Summary 
 Surprisingly, depressive symptoms increased over time for the whole sample, 
including cognitively normal subjects. As expected, atrophy in key regions (i.e., 
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amygdala, cACC, rACC, PCC) was moderated by group such that persons with cognitive 
impairment demonstrated faster decline than persons with normal cognition. Contrary to 
predictions, there were no significant associations between the rate of atrophy in neural 
regions and the rate of increase in depressive symptoms. Similarly, apathy did not 
moderate the rate of atrophy in any of the neural regions.  
4.3 Temporal Associations Between Neural Markers and NPS 
Temporal precedence of neural markers and depressive symptoms and apathy was 
assessed with lagged predictor and outcome models. Separate models were planned for 
each combination of predictor and outcome variables, resulting in 10 models. However, 
lagged predictor and outcomes models as outlined above were not able to converge in 
models including apathy, so traditional cross-lagged models were used to assess for 
temporal precedence of neural precursors and apathy. Such models defined specific 
predictive pathways (e.g., whether amygdala volume at baseline predicted apathy scores 
at the next timepoint), rather than estimating an overall mean association between neural 
volume at the previous timepoint and current apathy scores.  
4.3.1 Depressive Symptoms 
As outlined above, temporal precedence of neural markers and depressive 
symptoms was assessed with lagged predictor and outcome models. These models allow 
for determination of whether there is an association between current depressive 
symptoms and prior neural volume, and vice versa. Amygdala volume and DMN 
connectivity predicted depressive symptoms at the subsequent timepoint (Table 5). No 
other neural markers predicted later depressive symptoms. Depressive symptoms also 
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predicted amygdala volume at the subsequent timepoint, indicating a bidirectional 
relationship.  
4.3.2 Apathy 
Cross-lagged panel models were conducted with apathy and neural markers due to 
failure of lagged predictor models to converge. In these models, both autoregressive and 
predictive pathways were estimated to determine the association between neural volume 
and apathy at the next timepoint, controlling for the influence of prior apathy. The data 
did not support inclusion of a group variable in these analyses, so models were run only 
in the CI group (i.e. persons that start the study as MCI or progress from CN to MCI 
during the study). A model including apathy and DMN connectivity did not converge due 
to insufficient observations, and was thus excluded from the planned analyses.  
 Stability paths for both apathy and neural markers were significant or trending for 
all models (Table 6). That is, earlier apathy scores predicted later apathy scores and 
earlier neural volumes predicted later neural volumes. Amygdala volume and PCC 
volume at six months predicted subsequent apathy scores. However, contrary to 
expectations, there was not a consistent pattern of earlier neural volume predicting later 
apathy scores.  
4.3.3 Summary 
 There was partial support for the hypothesis that decline in key neural markers 
would predict subsequent increase in depressive symptoms and apathy. Specifically, 
lesser amygdala volume predicted greater depressive symptoms at the subsequent 
timepoint. However, the inverse was also true; greater depressive symptoms predicted 
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lesser amygdala volume at the subsequent timepoint. Greater DMN connectivity 
predicted greater depressive symptoms at the subsequent timepoint, contrary to 
predictions. Lesser amygdala and PCC volume at the six month visit predicted greater 
likelihood of apathy at the subsequent timepoint; however, this pattern was not replicated 
across any other timepoints.  
4.4 Associations Between Growth in NPS and Neural Markers and Conversion 
 To assess Aim 2—whether change in depression, apathy, and neural markers is 
associated with greater likelihood of progression of disease—a between-subjects variable 
was added to parallel process models that separated subjects into those whose diagnosis 
stayed stable throughout the study and those who converted (i.e., CN to MCI or AD; MCI 
to AD). When entered into the model alone, the slope of change in depressive symptoms 
was significantly associated with greater likelihood of conversion (OR = 6.60, 95%CI: 
1.15-37.71). That is, a more positive slope of change in depression over time was 
associated with a greater likelihood of progression of disease. Additionally, a higher 
likelihood of conversion was associated with greater atrophy over time in the amygdala 
(OR = 0.32, 95%CI: 0.21-0.49), cACC (OR = 0.55, 95%CI: 0.40-0.76), rACC (OR = 
0.77, 95%CI: 0.60-0.98), and PCC (OR = 0.66, 95%CI: 0.56-0.79), but not DMN 
connectivity (OR = 9.96, 95%CI: 0.012-8046.56). 
 Growth curves could not be reliably estimated for apathy due to limited within-
person variability. Thus, the direct association between change in apathy and conversion 
of disease was not assessed. However, persons with apathy at any point of the study 
(23.1% of sample) were more likely to progress than those without apathy, c2(1, N=563) 




 Consistent with predictions, the slope of increase in depressive symptoms and the 
rate of atrophy in key neural regions (i.e., amygdala, cACC, rACC, PCC) predicted 
likelihood of conversion (i.e., CN to MCI or MCI to AD). That is, greater rate of increase 
in depressive symptoms, and greater rate of atrophy in neural structures, predicted greater 
likelihood of disease progression. Additionally, as expected, the presence of apathy was 










The current study aimed to determine longitudinal associations between 
neuropathological changes in emotion centers in the brain and symptoms of depression 
and apathy in MCI. Consistent with expectations, there was some indication that decline 
in neural structures and circuits that support emotion function predicts increase in 
symptoms of depression and apathy. These results are intriguing because they provide 
preliminary support for the shared neuropathological model of NPS in MCI, which posits 
that symptoms of depression and apathy reflect noncognitive manifestations of 
underlying disease-specific neurodegeneration (Geda et al., 2013; Porsteinsson & 
Antonsdottir, 2015). Further, cortical volumes in emotion centers decreased more rapidly 
in persons who experienced cognitive impairment or cognitive decline than persons who 
remained cognitively stable. Faster atrophy in neural structures that support emotion 
function was associated with greater likelihood of  progression of disease, both from 
normal cognition to MCI and from MCI to AD.  Thus, early neuropathological changes in 
emotion circuitry may serve as prognostic markers for persons with aMCI.  
5.1 Longitudinal Change in NPS and Neural Markers 
Neurodegeneration may occur in emotion centers early in the AD disease process, 
even before onset of the cognitive symptoms that form the basis for diagnosis of aMCI 
(e.g., Peterson et al., 2009). As noted above, there was faster atrophy in the amygdala, 
ACC, and PCC in persons who progressed from cognitively normal to cognitively 
impaired than in persons who remained cognitive normal throughout the study.   
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In contrast, depressive symptoms were not a significant predictor of cognitive 
progression. Unexpectedly, depressive symptoms increased over time in persons who did 
and did not develop cognitive impairment.  Increases in depressive symptoms over time 
were expected in persons with cognitive impairment because extant research supports 
increase in severity of depressive symptoms along the AD disease spectrum (e.g., Di Iulio 
et al., 2010). Increases in depressive symptoms were not expected in persons who 
remained cognitive stable.  Indeed, there are well-established patterns of increased 
emotional well-being in healthy aging (e.g., Cacioppo et al. 2008; Carstensen et al., 2011; 
Mikels et al., 2014), although some studies report mixed findings, similar to the current 
data (e.g., Andreescu et al., 2008; Huang, et al., 2011).  That both cognitively intact and 
cognitively impaired groups evidenced significant increase in symptoms of depression 
over time argues against a purely neuropathological etiology for depressive symptoms in 
MCI.  
Delineating the etiology and impact of depressive symptoms on cognition in old 
adulthood has long proven challenging due to heterogeneity in the onset and nature of 
depressive symptoms (e.g., Fiske et al., 2009). It may be necessary to distinguish between 
new-onset depressive symptoms and exacerbation of long-standing depressive symptoms 
in late life in order to more accurately determine the prognostic value of depressive 
symptoms in early stages of AD.   New-onset depressive symptoms are more likely to 
reflect incipient neurodegeneration than symptoms with onset earlier in life, which may 
be exacerbated by—but are less likely to be primarily caused by—neurodegeneration. 
Consistent with prior findings (e.g., Guercio et al., 2015), symptoms of apathy 
were more prevalent among participants that entered the study with, or developed, 
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cognitive impairment than among participants that remained cognitively intact 
throughout. Apathy is common in many neurological disorders (e.g., Ishii et al., 2009), 
but is not common in otherwise healthy older adults. In contrast, depressive symptoms 
are less specific to neurological conditions and are more commonly found in otherwise 
healthy older adults without cognitive deficits. Group differences in apathy, but not 
depressive symptoms, may thus reflect the relative rarity of apathy in healthy older 
adults. 
5.2 Associations Between Neural Markers and Neuropsychiatric Symptoms 
Whereas there was evidence of atrophy in neural structures and increase in NPS 
over the course of the study, there was no evidence of concurrent associations between 
change in neural markers and change in symptoms of depression or apathy. Contrary to 
expectations, greater atrophy in neural markers was not associated with greater increase 
in depressive symptoms. Similarly, atrophy in neural markers was not different for 
persons with and without apathy.  
 In contrast, there was partial evidence for neural markers predicting later 
symptoms of depression and apathy. Specifically, lesser amygdala volume was associated 
with greater depressive symptoms a year later. Unexpectedly, the inverse of this 
relationship was also significant, such that greater depressive symptoms predicted lesser 
amygdala volume at the subsequent timepoint. Thus, associations between amygdala 
volume and depressive symptoms may be more accurately characterized as a feedback 




Another curious finding was that greater DMN connectivity predicted greater 
depressive symptoms at the subsequent timepoint, contrary to predictions. It is possible 
that greater DMN connectivity may reflect an increase in maladaptive self-reflective 
processes often seen in depression (e.g., rumination). However, prior findings about the 
association between DMN connectivity and depressive symptoms are mixed (Berman et 
al., 2014; Wang et al., 2012), and continued investigation is needed to determine whether 
the association between increased DMN connectivity and subsequent increase in 
depressive symptoms is replicated along the AD disease spectrum.  
Whereas there was not a pattern of earlier neural markers predicting later 
symptoms of apathy, an isolated finding indicated that volume in certain neural structures 
(i.e., amygdala and PCC volume) at the six month visit significantly predicted presence 
of apathy at the one year timepoint. There is not a theoretical reason that these particular 
timepoints would reveal a significant relationship between atrophy and apathy, especially 
since participants entered into the study at different chronological times and with 
different levels of cognitive impairment. As will be discussed in more detail below, a 
sample with greater prevalence of apathy will be better suited to pursue this line of 
inquiry.  
5.3 Association Between Depressive Symptoms, Apathy, and Progression of Disease 
It is well-established that symptoms of depression in MCI are associated with risk 
for conversion to AD (e.g., Lu et al., 2009; Van der Mussele et al., 2014). The current 
study similarly found an association between growth in depressive symptoms and 
conversion to AD. Additionally, steeper increase in depressive symptoms was associated 
with conversion even in the prodromal stage of the disease (i.e., CN to MCI). Thus, 
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depressive symptoms may be an early risk factor for disease progression even before the 
onset of objective cognitive decline.  
Apathy also was associated with greater likelihood of progression of disease, 
consistent with evidence indicating that apathy serves as a risk factor for conversion from 
MCI to AD (e.g., Palmer et al., 2010; Richard et al., 2012; Ruthirakuhan et al., 2019). 
The current results indicate that apathy might be a risk factor for progression of cognitive 
impairment even in the prodromal stage of AD.  Similarly, other studies find that apathy 
in cognitively healthy older adults is associated with cognitive decline (Clarke et al., 
2010), higher likelihood of incident MCI (Geda et al., 2014), and development of 
dementia over the following decade (Bock et al., 2020).  Thus, apathy at any stage of the 
AD disease process, including prior to onset of cognitive symptoms, may signal greater 
risk for progression of disease. 
5.4 Association Between Neural Changes and Progression of Disease 
Faster atrophy in the amygdala, ACC, and PCC was associated with greater 
likelihood of conversion from CN to MCI and from MCI to AD. This finding supports 
the shared neuropathological model (Geda et al., 2013; Porsteinsson & Antonsdottir, 
2015) by establishing a role for neurodegeneration in emotion centers in the brain in 
predicting faster progression of disease. Prior research has mainly focused on 
associations between cross-sectional cortical volume in the medial temporal lobes, 
including the hippocampus and the entorhinal cortex (e.g., Apostolova et al., 2006; 
Devadand et al., 2007; Mitolo et al., 2019; Yi et al., 2016) and subsequent risk for 
conversion from MCI to AD. The current results expand on the extant literature by 
establishing associations between volume loss in the limbic system and subsequent 
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progression of disease, even before diagnosis of MCI. The current results also focus 
specifically on atrophy, not cross-sectional volume, of brain structures, allowing for a 
more direct link between the neurodegenerative process and clinical symptoms. 
Longitudinal MRI tracking of atrophy in brain structures that support emotion function 
may represent a clinically useful metric of risk for conversion from MCI to AD. 
5.5 Support for Theoretical Models of Neuropsychiatric Symptoms in MCI 
As previously noted, findings from the current study provide partial support for 
the shared neuropathological model of NPS in MCI, which asserts that NPS are 
noncognitive manifestations of underlying AD-related neurodegeneration. Specifically, 
as discussed above, there was evidence of faster atrophy in the CI group than the CN 
group in areas of the brain essential for emotion processing and regulation (i.e., 
amygdala, ACC, PCC). The current findings of accelerated atrophy in emotion centers of 
the brain extend prior applications of the shared neuropathological model in AD to the 
prodromal and MCI stages of the disease (Van Dam et al., 2016).  
The shared neuropathological model of NPS inherently assumes that changes in 
neural structures and circuits precede changes in symptoms of depression and apathy. 
Results did not demonstrate a pattern of consistent findings along these lines. Whereas 
amygdala and PCC volume at six months negatively predicted the likelihood of 
endorsement of apathy at the subsequent timepoint, no other temporal associations were 
found between neural symptoms and later apathy. Additionally, there was a bidirectional 
relationship between amygdala volume and depressive symptoms, which may argue for a 
more complex relationship between neural changes and depressive symptoms than is 





Conclusions from the present study should be interpreted with several limitations 
in mind.  First, there were low levels of endorsement of depressive symptoms and apathy 
in the sample. Indeed, limited variability in apathy ratings precluded execution of certain 
planned analyses. There are several potential reasons for low endorsement of depressive 
symptoms and apathy in the current sample. There is evidence from community samples 
that NPS may arise before cognitive symptoms in most persons that go on to develop 
MCI and AD (Wise et al., 2019). However, enrollment criteria for ADNI excluded 
subjects with depressive symptoms (i.e., GDS > 6), which may have limited the 
prevalence and variability of NPS in the current sample by excluding persons on the 
disease spectrum whose first symptoms were neuropsychiatric rather than cognitive. It is 
also possible that early symptoms of depression and apathy in MCI are subtle and 
difficult to assess with the abbreviated symptom scales included in ADNI (i.e., GDS-SF, 
NPI-Q).  
Second, the sample is almost entirely White and relatively highly educated. 
Previous studies have established increased prevalence of AD in Black and Latinx older 
adults, which may be related to health disparities driven by systemic racism (e.g., 
Mayeda et al., 2016; Meeker et al., 2021).  Results may not generalize to samples with 
greater racial, ethnic, and socioeconomic diversity given the impact of psychosocial 
factors on health outcomes and cognitive function. Additionally, sex differences in the 
associations between neural changes, neuropsychiatric symptoms, and disease 
progression were not investigated.  Sex is a potentially important moderator variable 
 
 35 
because some studies have identified sex differences in the prevalence of 
neuropsychiatric symptoms (e.g., Inamura et al., 2020),.  
Third, measurement of depressive symptoms was limited to a brief questionnaire, 
which did not allow for more granular examination of subtypes of symptoms (e.g., 
physical vs. cognitive vs. affective). Additionally, apathy was assessed with one item on 
the NPI-Q, and was rated by research participants’ care partners, rather than the research 
participants themselves. Apathy ratings may thus be more reflective of participants’ 
behavior, rather than the internal experience of reduced motivation or interest.  
5.7 Future Directions 
The current study identified associations between change in neural markers of 
emotion dysregulation and change in symptoms of depression and apathy in persons with 
normal cognition and MCI. An important step for future research will involve testing the 
aims of the current study in a sample that more accurately reflects the range of NPS 
found in MCI. Further, it may be useful to investigate the current hypotheses in a sample 
that includes persons with mild AD at baseline. NPS are more frequently reported as the 
disease progresses (e.g., Di Iulio et al., 2010; Lyketsos et al., 2002), so including subjects 
that have progressed farther along the AD disease spectrum may allow for more reliable 
estimation of associations between NPS and underlying neural changes across the disease 
process.  
The current study focused exclusively on symptoms of depression and apathy, not 
NPS more generally. Future research is needed to determine whether disruption in 
emotion centers in the brain is predictive of development of NPS overall, or if different 
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areas of the brain are associated with development of different symptoms (e.g., anxiety 
versus agitation).  
There were significant associations between amygdala volume and later 
symptoms of apathy, whereas there was a bidirectional relationship between amygdala 
volume and depressive symptoms. Further research is needed to determine whether there 
is a reliable, predictive association between amygdala atrophy and development of 
depression and apathy. The bidirectional relationship between amygdala volume and 
depressive symptoms may indicate a more complex feedback loop between amygdala 
atrophy and development of NPS than is described by the shared neuropathological 
model. Research into alternative theories of NPS in AD might compliment the current 
research and advance efforts to determine specific mechanisms of the development of 
NPS in aMCI. 
The long term aim of this line of research is to characterize the etiology and 
consequences of affective dysregulation in persons with MCI and AD. To this end, it may 
be important to expand the operationalization of affective dysregulation to include 
specific behavioral markers, rather than using depression and apathy as proxies for 
affective dysregulation. Such studies would allow for development of a better 
understanding of how degeneration of emotion centers in the brain manifests in daily life 
and by which specific mechanisms these changes lead to observed functional and 
behavioral difficulties. Clarification of the neurobiology of NPS in aMCI may elucidate 
why standard psychopharmacological treatments for apathy and depression symptoms are 






Sample Characteristics and Descriptive Statistics 
 
Note. CDR = Clinical Dementia Rating scale. MMSE = Mini Mental State Exam. GDS = 
Geriatric Depression Scale Short Form. Apathy scores were dichotomized to reflect 
presence versus absence of apathy.  
*p < .05. **p < .01. ***p < .001. 
 
  
Variable Baseline CN 
n = 224 
M (SD) or % 
Baseline MCI 
n = 339 
M (SD) or % 
Test 
Statistic 
t or c2 
Age 73.46 (6.00) 72.38 (7.28) 1.84 
Female 52.7% 44.0% 4.12* 
Race   13.26* 
    White 91.1% 95.0%  
    Black 5.8% 1.5%  
    Native American -- 0.3%  
    Asian/Pacific Islander  0.9% 1.5%  
    Multiracial 2.2% 0.9%  
Ethnicity   7.60* 
    Hispanic/Latino 5.4% 2.1%  
    Non-Hispanic/Latino 93.8% 97.9%  
Education 16.63 (2.52) 15.99 (2.78) 2.80** 
Baseline CDR 0.65 (0.22) 1.52 (0.89) 28.74*** 
Baseline MMSE 29.01 (1.21) 27.86 (1.73) 9.13*** 
Baseline GDS-SF 1.84 (1.13) 2.84 (1.54) 8.77*** 
Baseline Apathy 2.8% 20.1% 33.84*** 
Years of follow-up 3.46 (1.95) 2.71 (1.15) 5.20*** 





Between-Subject Correlations Between Study Variables and Covariates  
 
Variable 1. 2. 3. 4. 5. 
1. Age --     
2. Education -.07 --    
3. GDS -.10* -.07 --   





  .13** .28*** -- 
Note. GDS = Geriatric Depression Scale Short Form. Apathy scores were dichotomized 
to reflect presence versus absence of apathy. Conversion reflects a dichotomous variable 
indicating whether disease status was stable or progressed over the course of the study. 
Spearman’s ρ is provided for all correlations with Apathy and Conversion.  







Parameter Estimates for Parallel Process Models Predicting Longitudinal Associations 
Between Depressive Symptoms and Neural Markers 
  Baseline Slope 
 Parameter g (se) g (se) 
Model 1 GDS 3.67 (0.30)*** 0.12 (0.044)** 
      Group -1.70 (0.20)*** 0.025 (0.078) 
      Age -0.049 (0.014)*** 0.014 (0.005)* 
      Education 0.002 (0.035) -0.029 (0.014)* 
 Amygdala Volume 13.41 (0.11)*** -0.17 (0.11)*** 
      Group 0.86 (0.20)*** 0.10 (0.020)*** 
      Age -0.10 (0.014)*** -0.005 (0.001)** 
      Education 0.088 (0.035)* 0.000 (0.004) 
Covariances GDS Slope*NeurSlope -0.004 (0.007) 
 GDSInt*GDSSlope 0.044 (0.083) 
 NeurInt*NeurSlope 0.061 (0.020)** 
Model 2 GDS 3.70 (0.11)*** 0.12 (0.44)** 
      Group -1.7 (0.20)*** 0.027 (0.078) 
      Age -0.049 (0.014)*** 0.014 (0.005)* 
      Education 0.002 (0.035) -0.029 (0.014)* 
 Caudal ACC Volume 19.17 (0.18)*** -0.17 (0.015)*** 
      Group 0.013 (0.022) 0.079 (0.026)** 
      Age 0.061 (0.055) -0.003 (0.002) 
      Education 0.199 (0.32) -0.007 (0.005) 
Covariances GDS Slope*NeurSlope 0.011 (0.009) 
 GDSInt*GDSSlope 0.061 (0.082) 
 NeurInt*NeurSlope -0.143 (0.041)** 
Model 3 GDS 3.70 (0.11)*** 0.12 (0.044)** 
      Group -1.70 (0.20)*** 0.024 (0.078) 
      Age -0.049 (0.014)*** 0.013 (0.005)* 
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      Education 0.002 (0.035) -0.029 (0.014)* 
 Rostral ACC Volume 23.22 (0.20)*** -0.17 (0.018)*** 
      Group -0.46 (0.36) 0.13 (0.031)*** 
      Age 0.058 (0.025)* -0.004 (0.002) 
      Education 0.15 (0.063)* -0.001 (0.006) 
Covariances GDS Slope*NeurSlope 0.013 (0.010) 
 GDSInt*GDSSlope 0.058 (0.048) 
 NeurInt*NeurSlope -0.14 (0.014)* 
Model 4 GDS 3.70 (0.11)*** 0.12 (0.44)** 
      Group -1.70 (0.20)*** 0.025 (0.078) 
      Age -0.049 (0.014)*** 0.014 (0.005)* 
      Education 0.002 (0.035) -0.028 (0.014)* 
 PCC Volume 30.09 (0.20)*** -0.039 (0.024)*** 
      Group 0.47 (0.37) 0.20 (0.043)*** 
      Age -0.061 (0.025)* -0.001 (0.003) 
      Education 0.097 (0.063) -0.007 (0.008) 
Covariances GDS Slope*NeurSlope -0.006 (0.015) 
 GDSInt*GDSSlope 0.050 (0.083) 
 NeurInt*NeurSlope -0.010 (0.073) 
Model 5 GDS 3.70 (0.11)*** 0.12 (0.44)** 
      Group -1.71 (0.20)*** 0.026 (0.078) 
      Age -0.049 (0.014)*** 0.013 (0.005)* 
      Education 0.002 (0.035) -0.029 (0.014)* 
  DMN Connectivity 9.77 (0.19)*** 0.16 (0.10) 
      Group 0.15 (0.33) -0.086 (0.17) 
      Age -0.013 (0.024) -0.007 (0.015) 
      Education 0.064 (0.064) -0.005 (0.035) 
Covariances GDS Slope*NeurSlope -0.025 (0.005) 
 GDSInt*GDSSlope 0.059 (0.082) 
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 NeurInt*NeurSlope 0.074 (0.20) 
Note. Age and education were grand mean centered in all models. Group was coded such 
that intercept values reflect the average for the cognitively impaired group. GDS = 
Geriatric Depression Scale. GDSSlope = slope of change in GDS scores over time. 
NeurSlope = slope of change in neural marker over time. GDSInt = mean GDS score at 
baseline. NeurInt = mean value for neural marker at baseline. ACC = anterior cingulate 
cortex. PCC = posterior cingulate cortex. DMN = default mode network. 











cACC Volume rACC Volume PCC Volume DMN Connectivity 
Parameter g (se) g (se) g (se) g (se) g (se) 
Intercept 14.07 (0.17)*** 19.072 (0.27)*** 22.93 (0.31)*** 29.61 (0.31)*** 9.92 (0.27)*** 
     Age -0.10 (0.014)*** -0.014 (0.022) 0.055 (0.025)* -0.060 (0.025)* -0.014 (0.024) 
     Education 0.088 (0.035)* 0.061 (0.055) 0.15 (0.062)* 0.098 (0.063) 0.07 (0.064) 
     Apathy -0.84 (0.69) -1.51 (1.08) -2.53 (1.23)* 0.29 (1.25) -0.056 (0.41) 
     Group -0.89 (0.22)*** 0.13 (0.35) 0.41 (0.39) 0.44 (0.40) -0.16 (0.36) 
     ApathyXGroup 0.77 (0.73) 1.44 (1.15) 2.14 (1.30) -0.13 (1.33) -- 
Slope -0.060 (0.017)*** -0.087 (0.022)*** -0.038 (0.026) -0.20 (0.035)*** 0.084 (0.13) 
     Age -0.005 (0.001)*** -0.003 (0.002) -0.004 (0.002)* -0.001 (0.003) -0.007 (0.015) 
     Education -0.001 (0.004) -0.008 (0.005) -0.002 (0.006) -0.010 (0.007) -0.010 (0.034) 
     Apathy -0.016 (0.066) -0.012 (0.085) -0.026 (0.10) 0.054 (0.14) 0.016 (0.21) 
     Group -0.078 (0.022)*** -0.044 (0.028) -0.10 (0.034)** -0.13 (0.045)** 0.072 (0.18) 
     ApathyXGroup -0.075 (0.071) -0.11 (0.091) -0.057 (0.11) -0.29 (0.15) -- 
Note. Age and education were grand mean centered in all models. Group was coded such that intercept values reflect the average for 
the cognitively impaired group. ApathyXGroup reflects the interaction between the binary apathy variable and group. cACC = caudal 
anterior cingulate cortex. rACC = rostral anterior cingulate cortex. PCC = posterior cingulate cortex. DMN = default mode network.  







Parameter Estimates for Lagged Predictor and Outcome Models with Depressive 
Symptoms and Neural Markers 
 Lagged Predictor Lagged Outcome 
Outcome Variable g (95% CI) g (95% CI) 
Amygdala Volume -1.06 (-1.69 to -0.29) -0.033 (-0.060 to -0.002) 
Caudal ACC Volume -0.080 (-0.63 to 0.50) -0.025 (-0.063 to 0.014) 
Rostral ACC Volume -0.25 (-0.15 to 0.67) -0.014 (-0.060 to 0.038) 
PCC Volume 0.17 (-0.062 to 0.44) -0.030 (-0.073 to 0.008) 
DMN Connectivity 0.25 (0.093 to 0.39) -0.033 (-0.33 to 0.21) 
Note. ACC = anterior cingulate cortex. PCC = posterior cingulate cortex. DMN = default 









Parameter Estimates for Cross-Lagged Panel Analyses with Apathy and Neural Markers 
 








Stability Paths     
    Ap0 à Ap1 1.09 (0.55)* 0.98 (0.51) + 1.03 (0.51)* 0.95 (0.48) + 
    Ap1 à Ap2 0.84 (0.20)*** 0.82 (0.19)*** 0.81 (0.19)*** 0.84 (0.19)*** 
    Ap2 à Ap3 1.33 (0.45)** 1.44 (0.48)** 1.45 (0.46)** 1.32 (0.40)** 
    Neur0 à Neur1 0.98 (0.020)*** 0.97 (0.027)*** 0.96 (0.022)*** 0.99 (0.023)*** 
    Neur1 à Neur2 1.01 (0.016)*** 1.01 (0.027)*** 1.01 (0.029)*** 0.96 (0.026)*** 
    Neur2 à Neur3 1.00 (0.029)*** 0.99 (0.017)*** 1.01 (0.027)*** 1.07 (0.030)*** 
Cross-Lagged Paths     
    Neur0 à Ap1 -0.38 (0.54) -0.11 (0.26) -0.18 (0.26) 0.17 (0.21) 
    Neur1 à Ap2 -1.17 (0.46)* -0.61 (0.33)+ -0.63 (0.33)+ -0.58 (0.26)* 
    Neur2 à Ap3 -1.47 (1.31) 1.01 (0.78) 0.84 (0.67) -0.42 (0.47) 
    Ap0 à Neur1 -0.025 (0.033) -0.030 (0.029) 0.002 (0.038) 0.023 (0.036) 
    Ap1 à Neur2 -0.008 (0.008) -0.018 (0.010)+ -0.026 (0.017) -0.005 (0.014) 
    Ap2 à Neur3 -0.010 (0.008) 0.004 (0.011) -0.001 (0.012) -0.011 (0.010) 
Concurrent Covariance     
    Ap0*Neur0 0.019 (0.016) 0.012 (0.013) 0.004 (0.011) 0.004 (0.012) 
    Ap1*Neur1 0.008 (0.011) 0.008 (0.010) 0.010 (0.015) -0.017 (0.014) 
    Ap2*Neur2 -0.015 (0.011) 0.001 (0.013) -0.036 (0.019)+ 0.002 (0.016) 
    Ap3*Neur3 -0.006 (0.031) -0.054 (0.041) -0.096 (0.046)* -0.036 (0.048) 
Note. All models controlled for patient age and education. cACC = caudal anterior cingulate cortex. rACC = rostral anterior cingulate 
cortex. PCC = posterior cingulate cortex. Ap = Apathy score. Neur = neural marker. 







Flowchart of Subject Groups 
 
563 Eligible subjects 
339 MCI at 
baseline 





















Note. Solid lines represent parameter estimates for pathways of interest; dotted lines 
reflect parameter estimates for covariates in the model. NPS = neuropsychiatric 
symptom. Group represents cognitive normal subjects versus those that developed 
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